Ja DE Þkte med de 214k aksjene og er nÄ kommet opp i 16,21%. De andre 3 SEB kontoene pÄ top ligger i ro, mens den fjerde SEB kontoen Þkte litt og ligger med litt under 900 000. Den kontoen har solgt seg ned fra 1,500,000 aksjer det siste Äret, men nÄ Þker interessant.
3 Likes
Meget interessant utvikling. Spennende at Briarwood og Seb kontoene har over 30% samlet.
2 Likes
At Briarwood kjÞper en sÄ stor post var en fantastisk beroligende melding Ä fÄ nÄ i helgen! I stedet for Ä lure pÄ om man burde selge seg ut og ta nok et tragisk tap, kan man heller vurdere om man bÞr benytte seg av billigsalget og kjÞpe mer!
1 Like
Hvor stor andel har de nÄ? Flaggegrense snart?
Men var det ikke SEB kontoene som ble mistenkt for Ă„ holde kursen nede?
Er det ikke teoretisk mulig att Briarwood stÄr bak flere av de?
Kjekkere lesning dette enn Þrten grunnlÞse innlegg om at posten gikk direkte til shorting. Nok et tegn pÄ folk bÞr unngÄ nistirring pÄ aksjekursen minutt for minutt.
3 Likes
My opinion: Siden Donald Trump sin FDA sjef pick, Marty Makary, har mer fokus pÄ forebygging enn behandling sÄ vil ressursene i FDA i stÞrre grad konsentrert pÄ mindre kostands-krevende inngrep og behandlinger tidligere i sykdomsforlÞpet.
Han er ogsÄ data-driven, og liker klare retningslinjer.
SÄnn sett tror jeg Photocures produkter er blant vinnerne, og med bedre muligheter helt konkret, men ogsÄ relativt sett.
6 Likes
Ok, altsÄ:
SEB kontoen som var pÄ 21 plass blant de stÞrste aksjonÊrene er borte med sine 214.000 aksjer. Briarwood har nÄ 4.397.000 aksjer og eier da totalt 16,21% av alle aksjene. Norne har oppdatert liste.
De 4 SEB kontoene som ligger pÄ 2 til 5 plass har nÄ totalt 4.645.000 aksjer. De har 17,13% av alle aksjer.
4 plass minus 14.000 og 5 plass minus 50.000 aksjer siste mÄned. Andre og tredje plass ingen bevegelser.
4 Likes
Utover posten pĂ„ 214â er nomineekontoen fra JP M (3. stĂžrste eier) og et par andre SEB kontoer pĂ„ top 5 de stĂžrste nettoselgere sĂ„ langt i Q4. I sum omlag 170â er nettosolgt fra disse.
3 Likes
Kan jo ogsÄ nevnes at sjefshausseren som har handlet med aksjer og derivater siden 90 tallet har lettet pÄ beholdningen sin med et 5 siffret antall aksjer 
2 Likes
Hvem er sjefshauserren? 
handlet litt selv de siste dagen. Totalt 6500 aksjer nÄ, ingen storhai men alt hjelper vell pÄ:+1:
If you know you know
Med det volumet vi har i denne aksjen kunne du kjĂžpt for en tusing og likevel pushet opp kursenđ
⊠om den ikke ble manipulert ned igjen av algoritmer da ofc
Det har vÊrt ganske bra volum siste tre dagene. 80.000 aksjer i gÄr.
Ikke akkurat blÊrekreft men mÄlet om selvlysende celler er det jo noe kjent med. Noen son vil tipse respektive part?
Achieving breakthrough through âcombination innovationâ to fill the weakest link in cervical cancer prevention and treatment
At the much-anticipated 7th China International Import Expo (CIIE), the real-life exhibition of the full-chain cervical cancer prevention and control system is definitely one of the most attractive booths for visitors.
Cervical cancer is the only cancer with a clear cause, which is preventable and controllable. It is the type of cancer that the China Cancer Foundation focuses on. Yahong Hong Kong has worked with more than ten partners, including Roche Diagnostics Cervical Cancer Innovation Platform, Hologic Womenâs Health Diagnostics Innovation Center, and QIAGEN Smart Innovation Park, to restore the entire process of cervical cancer from prevention to screening and treatment, and has received support and guidance from the China Cancer Foundation.
In the whole chain of cervical cancer prevention and control system, the innovative product APL-1702 for non-invasive treatment of cervical precancerous lesions brought by Asieris Pharmaceuticals is undoubtedly the most dazzling. Its unique combination of innovative concepts integrates photosensitizers with 100 times increased absorption capacity, 635 nanometer wavelength, 7 milliwatt low-power LED red light, and a portable cervical photodynamic therapy system. It looks like a âLittle Red Riding Hoodâ and is expected to subvert the traditional âone-size-fits-allâ treatment pattern of cervical precancerous lesions surgery.
As the âlast line of defenseâ in the prevention and treatment of cervical cancer, high-grade squamous intraepithelial lesions (HSIL) are the most clinically valuable link, but at the same time, the most lacking link in clinical practice. Before this, âone-size-fits-allâ surgical treatment was the first choice for HSIL, but this was harmful to the patientâs cervical function. The emergence of âLittle Red Riding Hoodâ not only provides HSIL patients with a new option, but also redefines the treatment logic of HSIL.
In addition to filling unmet clinical needs, âLittle Red Riding Hoodâ is also a combination of innovative products. For the Chinese pharmaceutical industry, the success of âLittle Red Riding Hoodâ is also a cross-era milestone.
01
Innovation should not be "imprisoned"
In 2007, Steve Jobs redefined the mobile phone with the iPhone.
At the Apple conference that year, Jobs announced three new products: an iPad with a touch screen, a revolutionary mobile phone, and a groundbreaking Internet tool. Judging from Jobsâ description, these three products were not very revolutionary, and they were almost all mature products at the time. However, Jobsâs next words shocked everyone, because these three new products were not three independent products, but all gathered on the iPhone.
If we trace back to the origin, the iPhone does not have any essential technological breakthroughs. It is just a combination of three mature products into a brand new iPhone. So is the iPhone innovative? From the perspective of user experience, it has completely changed peopleâs traditional perception of mobile phones. It should not only be considered innovative, but also a cross-era innovative product. This is the magic of âcombinatorial innovationâ.
In fact, âcombinatorial innovationâ is not only applicable to the consumer sector, there are also many successful cases in the medical field.
Relying on the monopoly advantage of the core component charge-coupled device (CCD), Japanese soft lenses once established extremely solid industrial barriers in the world. Three Japanese companies, Olympus, Fujifilm, and PENTAX Medical, once accounted for more than 93% of the global market share.
However, the seemingly impregnable industry barriers were easily broken by a Danish cross-border company called Ambu. Ambu did not compete with the Japanese endoscope giant in technology, but started from the unmet clinical needs and combined disposable endoscope consumables with imaging systems to create a new product, disposable endoscopes. Since officially entering the endoscope track in 2009, Ambu has officially found new performance growth and achieved continuous revenue growth for 14 consecutive years.
Ambu is not a mature company that has been deeply involved in the endoscopy track for many years, but a thorough cross-border player. Before launching its first disposable soft bronchoscope aScope, Ambuâs main business was mainly resuscitation and medical training. However, such a layman has snatched the market from the Japanese soft endoscope giant and has become a force that cannot be ignored in the industry.
The core reason behind this is Ambuâs accurate insight into unmet clinical needs. At that time, soft endoscopes were medical devices that directly entered the natural lumen of the human body and were prone to infection due to incomplete cleaning. Even though the guidelines of the Society of Gastroenterology Nurses (SGNA) had clearly divided the follow-up of soft endoscopes into 43 steps, there was still a possibility of infection.
In 2006, American medical professor Seoane-Vazquez conducted a retrospective analysis, which counted all soft endoscope infections in the United States between 1974 and 2004. The results showed that a total of 10,989 patients had used contaminated examination instruments, of which 740 suffered infections. In 2002 alone, 414 patients at Johns Hopkins Hospital in the United States were exposed to bacterially contaminated endoscopes, resulting in 32 infections and 3 deaths.
Under the potential risk of infection due to contamination, no matter how clear the image of the endoscope is, it is difficult for patients to feel at ease. For patients at that time, the industry âfirst natureâ of soft endoscopes had quietly changed. An endoscope that completely eliminates the risk of infection is significantly better than an ordinary endoscope.
From these two cases, it is clear that great innovative products are not differentiated by innovative formats, but are necessarily born out of demand. Products that can meet clinical gaps are extremely creative products, and innovation should not be defined dogmatically.
02
Speak with results
Similar to its predecessors Apple and Ambu, Yahong Pharmaceuticalâs âLittle Red Riding Hoodâ is also a âcombination innovationâ product that focuses on actual unmet needs.
âLittle Red Riding Hoodâ is composed of three disruptive innovative technologies: patented fat-soluble photosensitizer (HAL), breakthrough ultra-low-power LED light source, and first-of-its-kind portable design. Its basic mechanism is not complicated, which is to use the interaction of photosensitizer, light, and oxygen to produce a highly selective photodynamic reaction to remove lesions in a targeted manner.
HPV-infected cells in the human body have abnormal proliferation and metabolism, so they absorb more photosensitizers, while normal cells do not. After being given an exogenous light source, the photosensitizers in abnormal cells will be excited to generate a large amount of energy, which is then transferred to molecular oxygen in the cells, producing a large amount of singlet oxygen and free radicals, ultimately killing the abnormal cells.
Figure: Principle of the âLittle Red Riding Hoodâ mechanism
This basic mechanism seems simple, but it is not easy to achieve results in clinical practice, and there are many difficulties.
The first is the problem of cell absorption of photosensitizers. Since traditional photosensitizers are mostly water-soluble, they are not easily absorbed by cells, and naturally cannot have a therapeutic effect. âLittle Red Riding Hoodâ pioneered the use of HAL, which can successfully penetrate the cell membrane and increase the selective absorption rate in diseased cells by nearly 100 times. It is precisely based on the super selectivity of HAL that âLittle Red Riding Hoodâ can significantly reduce the harm of drug concentration to the human body while ensuring the efficacy.
However, innovative photosensitizers alone are not enough, because the cervix is ââvery sensitive to temperature. Using ordinary light sources to irradiate the cervix will cause a burning sensation, and even worse, it will cause scalds. Therefore, the choice of light source is also very important. âLittle Red Riding Hoodâ uses a 635nm red LED light source with a power of only 7 milliwatts and an operating temperature of no more than 42 degrees Celsius, which is extremely gentle and comfortable for the human body.
In addition, the traditional HSIL treatment is time-consuming and labor-intensive, but the âLittle Red Riding Hoodâ pioneered a portable design, and the patient can leave after the doctor places it. The âLittle Red Riding Hoodâ has revolutionized the HSIL treatment scenario, not only does it not require the âpainâ of surgery, but it is also simple and convenient.
Relying on the combination of three disruptive innovative technologies, the clinical data of APL-1702, the âLittle Red Riding Hoodâ of Asieris Pharmaceuticals, is encouraging. In September this year, Asieris Pharmaceuticals announced that the results of the international multicenter Phase III clinical trial of APL-1702 were selected for the 27th National Congress of Clinical Oncology (CSCO), and published the analysis data of different age subgroups of the study on the pathological outcome rate and HPV clearance rate at 6 months in the form of a poster.
The data showed that based on the analysis of the pathological regression rate at the 6th month in different age subgroups (i.e., histopathological remission rate, defined as the proportion of subjects with histopathological regression to CIN1 or normal), the pathological regression rate of the APL-1702 group was 15% to 20% higher than that of the placebo control group, regardless of whether it was the âpopulation â„20 years and <30 years oldâ or the âpopulation â„30 years and <40 years oldâ. No cervical cancer events occurred in any age subgroup, suggesting that APL-1702 has significant therapeutic potential in the HSIL population aged 20 to 40 years.
Figure: Pathological outcome rates in different age subgroups at 6 months
In terms of HPV clearance rate, the APL-1702 group and the placebo control group showed an increase in the overall HPV clearance rate, HPV16+ clearance rate, and HPV16/18+ clearance rate in the ââ„20 years old and <30 years old populationâ. The proportion of â<20 years oldâ and ââ„40 years old populationâ in this study was relatively low, and the robustness of the results in this population requires verification with a larger sample size. Overall, APL-1702 not only promoted the reduction of HSIL to LSIL (Low-Grade Squamous Intraepithelial Lesion), but also demonstrated the ability to cause high-risk HPV viruses to turn negative.
Figure: HPV clearance rate in different age subgroups
As the worldâs first HSIL treatment product to obtain positive results in a Phase III registered clinical trial, the emergence of âLittle Red Riding Hoodâ APL-1702 is expected to allow HSIL to bid farewell to âone size fits allâ and move towards âtruly non-invasiveâ treatment.
If the breakthrough of âLittle Red Riding Hoodâ in HSIL treatment is a treasure, then HAL is the map to find the treasure, the breakthrough ultra-low-power LED light source is the tool to dig for the treasure, and the portable design is the key to open the treasure. Although HAL, cold light source and portable design are not the first inventions of Yahong, if we want to achieve such an effect in clinical practice, then the three innovative concepts are indispensable.
The difficulty that Yahong Pharmaceuticals encountered in the development of âLittle Red Riding Hoodâ lies not in the raw materials themselves, but in how to find the only correct answer from a large number of potential materials. âCombinatorial innovationâ does not pursue the process of innovation, but the result of ultimately solving practical problems. Isnât the essence of the currently popular dual-antibody drug a kind of âcombinatorial innovationâ?
03
What exactly is innovation?
Over the years, Chinaâs pharmaceutical industry has actually fallen into an âinnovationâ trap: too many people are innovating for the sake of innovation.
What is innovation? This is an unanswerable question, because all innovative drugs are now artificially defined concepts, and as long as they are defined by humans, there will inevitably be loopholes. For example, the famous âdeuterium substitutionâ technology, its essence is to replace the hydrogen in the organic compound molecules with its isotope deuterium, in order to circumvent patent barriers. Although the product after âdeuterium substitutionâ is a new molecule, is it really innovative?
Any innovation with utilitarian ideas should not be considered innovation. Real innovation must be based on unmet clinical needs and can effectively solve patientsâ real-life problems. For example, the iPhone successfully integrates multiple functions into one phone, so that people no longer need to carry so many other electronic products when they go out; for example, Ambu changed the frequency of use of endoscopes, and pioneered a solution to the infection problem that has plagued the industry for a long time.
Too many people have been stuck in traditional thinking for a long time. The development logic of any industry is not static, but constantly changes with the changes in clinical needs. The only thing that remains unchanged is that good products must be based on user needs.
Before the âLittle Red Riding Hoodâ, surgery could also treat HSIL, but âone size fits allâ had many hidden concerns, such as recurrence, pain, fertility, etc. The emergence of âLittle Red Riding Hoodâ provides patients with more options. Before surgery, they can try âLittle Red Riding Hoodâ first, thus avoiding the simple violence of âone size fits allâ.
Surgical treatment can certainly solve certain clinical needs, but when the industry has developed to a certain extent, the most urgent need of patients is not simple treatment, but how to treat with higher efficiency and lower loss. If efficacy is the âfirst priorityâ of medical products, when the âfirst priorityâ has been fully satisfied, then the first priority of the industry is actually quietly changing, such as the transformation of endoscopes to safety to avoid infection, and HSIL to a safer and more conservative treatment plan.
âLittle Red Riding Hoodâ can be regarded as a classic âdisruptive innovationâ. Although it is inconsistent with the development trend of the mainstream market, it often has a strong âdestructive powerâ in the industry because it thinks about the problem from the perspective of demand. âLittle Red Riding Hoodâ is actually quite enlightening for both practitioners and investors, that is, industrial changes often occur unexpectedly. Instead of desperately rolling inward, it is better to observe more. Involution will only destroy value, and innovation will only be born out of demand.
As the saying goes, you cannot see the true face of Mount Lu because you are in it. Many times, only by breaking away from the fixed mindset and not blindly competing internally, but thinking about problems from the perspective of actual clinical needs, may you get completely different results. Similarly, innovation should not be a label, but a real way to fill clinical gaps. With the success of âLittle Red Riding Hoodâ, âcombinatorial innovationâ may become a new path to fill clinical gaps, and Chinaâs pharmaceutical industry is expected to enter a new era of âcombinatorial innovationâ.
Editorâs note: This article is reprinted from the WeChat public account: Yiyao, author: Lin Pharmacist
10 Likes
Tror ikke det var feil Ă„ buy the dip.
1 Like
Der bikket de vel tresifret antall ganger i Ă„ bruke ordet:
innovation
Nesten sÄ man skulle tro de er- eller i det minste mener/forventer at de skal i innovasjonssporet / hurtigfila for godkjenning.
3 Likes
Google oversat:
Selvom HAL, kold lyskilde og bÊrbart design ikke er de fÞrste opfindelser af Yahong, hvis vi Þnsker at opnÄ en sÄdan effekt i klinisk praksis, sÄ er de tre innovative koncepter uundvÊrlige.
Mere: The difficulty that Yahong Pharmaceuticals encountered in the development of âLittle Red Riding Hoodâ lies not in the raw materials themselves, but in how to find the only correct answer from a large number of potential materials.
Google oversat:
Vanskeligheden, som Yahong Pharmaceuticals stĂždte pĂ„ i udviklingen af ââ"RĂžhĂŠtte", ligger ikke i selve rĂ„varerne, men i, hvordan man finder det eneste rigtige svar fra et stort antal potentielle materialer.
Er det bare mig eller er det oversĂŠttelse â det ser ud som det er Yahong`s opfindelse !!!
Lugter lidt af tyveri 
Dansken
De har kjĂžpt det, da er det ikke tyveri.
2 Likes